Merck carried off the prize in 1st Line NSCLC with KEYNOTE-021G and KEYNOTE-024 data Keytruda showed impressive results in 1L NSCLC both as a monotherapy and in combination with chemo. In the monotherapy study (KEYNOTE-024) focused on high PD-L1 expressors (TPS ≥50%), Keytruda gave superior results versus chemotherapy (mPFS: 10.3 Continue Reading
 Categories : Conference Coverage Posted by Sakshi Saini